A 3-(4-Nitronaphthen-1-yl) amino-benzoate analog as a Bifunctional AKR1C3 Inhibitor with AR Antagonist Activity: Head to Head Comparison with Other Advanced AKR1C3 Targeted Therapeutics

Drugs used for the treatment of castration resistant prostate cancer (CRPC) include Abiraterone acetate (Zytiga®) and Enzalutamide (XTANDI®). However, these drugs provide clinical benefit in metastatic disease for only a brief period before drug resistance emerges. One mechanism of drug resistance i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Steroid Biochem Mol Biol
Egile Nagusiak: Wangtrakuldee, Phumvadee, Adeniji, Adegoke O., Zang, Tianzhu, Duan, Ling, Khatri, Buddha, Twenter, Barry M., Estrada, Michelle A., Higgins, Tyler F., Winkler, Jeffrey D., Penning, Trevor M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6625945/
https://ncbi.nlm.nih.gov/pubmed/30641225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsbmb.2019.01.001
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak